Emend (Aprepitant) - Summary

EMEND SUMMARY

EMEND (aprepitant) is a substance P/neurokinin 1 (NK₁) receptor antagonist.

EMEND, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin (see DOSAGE AND ADMINISTRATION).

See all Emend indications & dosage >>

EMEND NEWS HIGHLIGHTS

Media Articles Related to Emend (Aprepitant)

3-Substituted Indolones As Novel Therapeutic Compounds For Neurodegenerative Conditions
Source: Multiple Sclerosis News From Medical News Today [2008.10.29]

MU Brain Imaging Center Provides Research For Autism, Schizophrenia And Parkinson's Disease
Source: Schizophrenia News From Medical News Today [2008.10.18]

Susceptibility To Cleft Palate Revealed By Genetic Profile
Source: Cleft Palate News From Medical News Today [2008.09.16]

New Drug Hope For Cystic Fibrosis Patients
Source: Cystic Fibrosis News From Medical News Today [2008.09.11]

Nausea and Vomiting
Source: MedicineNet Antiemetics Specialty [2008.04.29]

more >>

Published Studies Related to Emend (Aprepitant)

Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. [2008.08]

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. [2008.05.01]

A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans. [2008.04.01]

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. [2008.03.07]

Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. [2007.10.27]

more >>

Clinical Trials Related to Emend (Aprepitant)

ONO-7436 Phase II Study in Japan [Completed]

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals [Recruiting]

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) [Recruiting]

Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients [Recruiting]

A Randomized, Double-Blind Comparison of Oral Aprepitant Alone Versus Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting [Recruiting]

more >>